MVA-5T4联合低剂量环磷酰胺对转移性结直肠癌抗肿瘤免疫的影响:一项随机临床试验
这项单中心随机临床试验纳入55例标准化疗后疾病稳定的不可手术mCRC患者,随机分为观察等待、环磷酰胺、MVA-5T4及联合治疗四组,主要终点为第7周抗5T4免疫应答。结果显示MVA-5T4及联合组抗体应答显著高于无治疗组,MVA-5T4使基线抗5T4应答倍增者PFS和OS显著延长,未观察到3/4级不良事件。
要点
- MVA-5T4组与联合组第7周5T4特异性抗体应答显著高于无治疗组。
- MVA-5T4使16/35例患者基线抗5T4应答倍增,其PFS和OS显著延长。
- 环磷酰胺耗竭调节性T细胞独立延长PFS,但未增加MVA-5T4免疫应答。
核心结论
- 该初步随机临床免疫治疗研究显示mCRC患者获得显著生存获益。
- 环磷酰胺预先耗竭调节性T细胞未增加MVA-5T4疫苗产生的免疫应答。
- 环磷酰胺和MVA-5T4各自独立诱导有益的抗原特异性抗肿瘤免疫应答,延长生存且无毒性反应。
研究设计与样本
- 随机临床试验,单中心入组55例不可手术mCRC且标准化疗后疾病稳定的患者。
- 随机分为观察等待组(n=9)、仅环磷酰胺组(n=9)、仅MVA-5T4组(n=19)及MVA-5T4联合环磷酰胺组(n=18)。
- 2012年7月9日至2016年2月8日入组治疗,2016年12月13日完成随访,按意向治疗分析。
主要发现
- 环磷酰胺在27例接受MVA-5T4的患者中耗竭24例的调节性T细胞,独立延长PFS(5.0 vs 2.5个月;HR 0.48;95%CI 0.21-1.11;P=0.09)。
- 未观察到3级或4级不良事件。
关键数值与推荐
- 环磷酰胺组给药:50 mg每日两次,治疗第1至7天和第15至21天。
- MVA-5T4组给药:1×10^9 50%组织培养感染剂量肌肉注射,治疗第22、36、50、64、78和106天。
- 主要终点:治疗第7周产生的抗5T4免疫应答(5T4特异性T细胞和抗体水平)的幅度。
- 次要终点:抗5T4应答动力学分析、无进展生存期(PFS)和总生存期(OS)。
临床怎么用
- 对于标准化疗后疾病稳定的不可手术mCRC患者,MVA-5T4疫苗可能诱导抗5T4免疫应答并延长生存。
- 环磷酰胺和MVA-5T4可各自独立诱导有益的抗肿瘤免疫应答,且未观察到3/4级不良事件。
- 需更大规模临床试验进一步验证这些数据。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The success of immunotherapy with checkpoint inhibitors is not replicated in most cases of colorectal cancer; therefore, different strategies are urgently required. The oncofetal antigen 5T4 is expressed in more than 90% of cases of metastatic colorectal cancer (mCRC). Preliminary data using modified vaccinia Ankara-5T4 (MVA-5T4) in mCRC demonstrated that it safely induced serologic and T-cell responses. OBJECTIVE: To determine whether antitumor immunity in mCRC could be increased using MVA-5T4, metronomic low-dose cyclophosphamide, or a combination of both treatments. DESIGN, SETTING, AND PARTICIPANTS: In this randomized clinical trial, 55 patients with inoperable mCRC and prior stable disease after standard chemotherapy were enrolled at a single center and randomized to watch and wait (n = 9), cyclophosphamide treatment only (n = 9), MVA-5T4 only (n = 19), and a combination of MVA-5T4 and cyclophosphamide (n = 18). Patients were enrolled and treated from July 9, 2012, through February 8, 2016, and follow-up was completed on December 13, 2016. Data were analyzed based on intention to treat. INTERVENTIONS: Patients randomized to a cyclophosphamide group received 50 mg twice daily on treatment days 1 to 7 and 15 to 21. Patients randomized to a MVA-5T4 group received an intramuscular injection at a dose of 1 × 109 50% tissue culture infectious dose on treatment days 22, 36, 50, 64, 78, and 106. MAIN OUTCOMES AND MEASURES: The predefined primary end point was the magnitude of anti-5T4 immune responses (5T4-specific T-cell and antibody levels) generated at treatment week 7. Secondary end points included analysis of the kinetics of anti-5T4 responses, progression-free survival (PFS), and overall survival (OS). RESULTS: Fifty-two patients (38 men and 14 women; mean [SD] age, 64.2 [10.1] years) were included in the study analysis. The 5T4-specific antibody immune responses were significantly increased in the MVA-5T4 (83.41 [36.09] relative units [RU]; P = .02) and combination treatment (65.81 [16.68] RU; P = .002) groups compared with no treatment (20.09 [7.20] RU). Cyclophosphamide depleted regulatory T cells in 24 of 27 patients receiving MVA-5T4, independently prolonging PFS (5.0 vs 2.5 months; hazard ratio [HR], 0.48; 95% CI, 0.21-1.11; P = .09). MVA-5T4 doubled baseline anti-5T4 responses in 16 of 35 patients, resulting in significantly prolonged PFS (5.6 vs 2.4 months; HR, 0.21; 95% CI, 0.09-0.47; P < .001) and OS (20.0 vs 10.3 months; HR, 0.32; 95% CI, 0.14-0.74; P = .008). No grade 3 or 4 adverse events were observed. CONCLUSIONS AND RELEVANCE: This initial randomized clinical immunotherapy study demonstrates a significant survival benefit in mCRC. Prior depletion of regulatory T cells by cyclophosphamide did not increase immune responses generated by MVA-5T4 vaccination; however, cyclophosphamide and MVA-5T4 each independently induced beneficial antitumor immune responses, resulting in prolonged survival without toxic effects. Larger clinical trials are planned to further validate these data. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN54669986.
引用
- Scurr M, Pembroke T, Bloom A, et al. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017. PMID: 28880972. doi:10.1001/jamaoncol.2017.2579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。